scholarly journals Association of the CYP17 (T-34C) Polymorphism and the Risk of Acne Vulgaris: A Meta-Analysis

2018 ◽  
Author(s):  
Mazaher Ramezani ◽  
Elisa Zavattaro ◽  
Masoud Sadeghi
Keyword(s):  
Web Of Science ◽  
Skin Diseases ◽  
Genetic Relationships ◽  
Meta Analysis ◽  
Acne Vulgaris ◽  
Cochrane Library ◽  
Asian Ethnicity ◽  
Common Skin ◽  
The Relationship ◽  
Review Manager

Acne vulgaris is one of the most common skin diseases and genetic relationships have been documented. The aim was to evaluate the association of CYP17 (T-34C) polymorphism related to the risk of acne in a meta-analysis study. The databases (Scopus, Web of Science, PubMed, and Cochrane Library) were searched until September 2018 to check the relationship between acne risk and CYP17 (T-34C) polymorphism and impact of this polymorphism on severity of acne. We used Review Manager 5.3 software to analyze the data using OR and 95% CI to check this relationship. Four studies were included and analyzed in the meta-analysis. The OR in analysis of C versus T in acne patients compared to the healthy controls was 1.42 (P=0.02), in CC vs. TT was 1.54 (P=0.04), in TC vs. TT was 1.46 (P=0.12), in TC + CC vs. TT was 1.55 (P=0.04), and in CC vs. TT + TC was 1.39 (P=0.06). There was no acne risk related to CYP17 (T-34C) in none of genetic models in Caucasian ethnicity, whereas in Asian ethnicity, there was higher acne risk related to CYP17 (T-34C) without heterogeneity. The results of the present meta-analysis showed the presence of C allele and CC genotype of CYP17 polymorphism can be risk factors for acne, mainly in the Asian ethnicity.

scholarly journals Association between CYP3A5 Polymorphism and Statin-Induced Adverse Events: A Systemic Review and Meta-Analysis

2021 ◽  
Vol 11 (7) ◽  
pp. 677
Author(s):  
Jeong Yee ◽  
Hamin Kim ◽  
Yunhee Heo ◽  
Ha-Young Yoon ◽  
Gonjin Song ◽  
...  
Keyword(s):  
Adverse Events ◽  
Web Of Science ◽  
Meta Analysis ◽  
Statistical Significance ◽  
Systemic Review ◽  
Event Risk ◽  
Total Data ◽  
Lipophilic Statin ◽  
The Relationship ◽  
Review Manager

Purpose: Cytochrome P450 (CYP) is involved in the metabolism of statins; CYP3A5 is the main enzyme responsible for lipophilic statin metabolism. However, the evidence of the association between CYP3A5*3 polymorphism and the risk of statin-induced adverse events remains unclear. Therefore, this study aimed to perform a systematic review and meta-analysis to investigate the relationship between the CYP3A5*3 polymorphism and the risk of statin-induced adverse events. Methods: The PubMed, Web of Science, and EMBASE databases were searched for qualified studies published until August 2020. Observational studies that included the association between statin-induced adverse events and the CYP3A5*3 polymorphism were reviewed. The odds ratios (ORs) and 95% confidence intervals (CIs) were evaluated to assess the strength of the relationship. The Mantel–Haenszel method was used to provide the pooled ORs. Heterogeneity was estimated with I2 statistics and publication bias was determined by Begg’s and Egger’s test of the funnel plot. Data analysis was performed using Review Manager (version 5.4) and R Studio (version 3.6). Results: In total, data from 8 studies involving 1614 patients were included in this meta-analysis. The CYP3A5*3 polymorphism was found to be associated with the risk of statin-induced adverse events (*3/*3 vs. *1/*1 + *1/*3: OR = 1.40, 95% CI = 1.08–1.82). For myopathy, the pooled OR was 1.30 (95% CI: 0.96–1.75). The subgroup analysis of statin-induced myopathy revealed a trend, which did not achieve statistical significance. Conclusions: This meta-analysis demonstrated that the CYP3A5*3 polymorphism affected statin-induced adverse event risk. Therefore, CYP3A5 genotyping may be useful to predict statin toxicity.

scholarly journals Influence of NQO1 Polymorphisms on Warfarin Maintenance Dose: A Systematic Review and Meta-Analysis (rs1800566 and rs10517)

2021 ◽  
Vol 2021 ◽  
pp. 1-9
Author(s):  
Lihong Tian ◽  
Pingping Xiao ◽  
Bingrong Zhou ◽  
Yishan Chen ◽  
Lijuan Kang ◽  
...  
Keyword(s):  
Maintenance Dose ◽  
Meta Analysis ◽  
Warfarin Dose ◽  
Maintenance Dosage ◽  
Sensitivity Analyses ◽  
Cochrane Library ◽  
The Cochrane Library ◽  
The Relationship ◽  
Review Manager ◽  
Warfarin Maintenance Dose

This meta-analysis was conducted to analyze the effect of NQO1 polymorphism on the warfarin maintenance dosage. Using strict inclusion and exclusion criteria, we searched PubMed, EMBASE, and the Cochrane Library for eligible studies published prior to July 7, 2021. The required data were extracted, and experts were consulted when necessary. Review Manager Version 5.4 software was used to analyze the relationship between NQO1 polymorphisms and the warfarin maintenance dosage. Four articles involving 757 patients were included in the meta-analysis. Patients who were NQO1 rs10517 G carriers (AG carriers or GG carriers) required a 48% higher warfarin maintenance dose than those who were AA carriers. Patients with NQO1 rs1800566 CT carriers required a 13% higher warfarin dose than those who were CC carriers, with no associations observed with the other comparisons of the NQO1 rs1800566 genotypes. However, the results obtained by comparing the NQO1 rs1800566 genotypes require confirmation, as significant changes in the results were found in sensitivity analyses. Our meta-analysis suggests that the NQO1 rs10517and NQO1 rs1800566 variant statuses affect the required warfarin maintenance dose.

scholarly journals Association of LTF, ENAM, and AMELX polymorphisms with dental caries susceptibility: A meta-analysis

2020 ◽  
Author(s):  
Roohollah Sharifi ◽  
Sajjad Jahedi ◽  
Hamid Reza Mozaffari ◽  
Mohammad Moslem Imani ◽  
Masuod Sadeghi ◽  
...  
Keyword(s):  
Dental Caries ◽  
Web Of Science ◽  
Meta Analysis ◽  
Cochrane Library ◽  
Control Group ◽  
Case Group ◽  
Caries Risk ◽  
Increased Risk ◽  
Dental Caries Susceptibility ◽  
Review Manager

Abstract Background This meta-analysis evaluated the association of LTF, ENAM, and AMELX polymorphisms with dental caries susceptibility.Methods We searched the Scopus, PubMed/Medline, Web of Science, and Cochrane Library databases to retrieve articles published by October 2019. Review Manager 5.3 software was used to estimate the odds ratios (ORs) and 95% confidence intervals (CIs). The results of publication bias tests were retrieved by Comprehensive Meta-Analysis 2.0 software.Results A total of 150 relevant records were identified; out of which, 16 were entered into the analysis (4 studies assessed LTF, 11 ENAM, and 11 AMELX polymorphisms). Of all polymorphisms, there was a significant association only between ENAM rs3796704 polymorphism and dental caries susceptibility. Both ENAM rs3796704 and AMELX rs17878486 polymorphisms had a significant association with dental caries risk in the Caucasian ethnicity and the studies including caries-free control group.Conclusions The results of this meta-analysis showed that the G allele and the GG genotype of ENAM rs3796704 were associated with an increased risk of caries in the case group compared with the control group. But there was no association between LTF rs1126478, ENAM (rs1264848 and rs3796703), and AMELX (rs946252, rs17878486, and rs2106416) polymorphisms and dental caries susceptibility.

scholarly journals Clinicopathologic Relevance of Claudin 18.2 Expression in Gastric Cancer: A Meta-Analysis

2021 ◽  
Vol 11 ◽  
Author(s):  
Bogdan Silviu Ungureanu ◽  
Cristian-Virgil Lungulescu ◽  
Daniel Pirici ◽  
Adina Turcu-Stiolica ◽  
Dan Ionut Gheonea ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Overall Survival ◽  
Targeted Therapy ◽  
Odds Ratio ◽  
Web Of Science ◽  
Meta Analysis ◽  
Pathological Features ◽  
Potential Efficacy ◽  
The Relationship ◽  
Review Manager

An increasing number of tumor markers have been discovered to have potential efficacy as diagnostic and prognostic tools in gastric cancer. We aimed to assess putative correlations between claudin 18.2 expression and pathological or prognosis features in patients with gastric cancer. MEDLINE, Web of Science, EBSCO, and ClinicalTrials.gov were used to search for relevant studies from their inception to 30 October 2020. Finally, a total of six articles were included in this meta-analysis. Review Manager 5 software was applied to examine the heterogeneity among the studies and to calculate the odds ratio with 95% CI by selecting corresponding models, in evaluating the strength of the relationship. Publication bias test was also conducted. No bias and no significant correlations were found between CLDN 18.2 and TNM stages, Lauren classification, HER2, grading, or overall survival. This meta-analysis expounded that the relationship with CLDN 18.2 and pathological features depends on the percentage of staining of tumor cells for which CLDN 18.2 is considered positive. Our pooled outcomes suggest that targeted therapy for CLDN 18.2 could be effective if certain criteria were established.

scholarly journals ERCC1 rs11615 polymorphism and chemosensitivity to platinum drugs in patients with ovarian cancer: a systematic review and meta-analysis

2021 ◽  
Vol 14 (1) ◽  
Author(s):  
Yuqiang Zhang ◽  
Sufen Cao ◽  
Chunyu Zhuang ◽  
Jiacheng Chen ◽  
Xiaojing Chen ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Web Of Science ◽  
Meta Analysis ◽  
Asian Population ◽  
Caucasian Population ◽  
Cochrane Library ◽  
Platinum Drugs ◽  
China National Knowledge Infrastructure ◽  
Knowledge Infrastructure ◽  
The Relationship

Abstract Objective To explore the relationship between ERCC1 rs11615 polymorphism and chemosensitivity to platinum drugs in ovarian cancer by the method of meta-analysis. Methods Pubmed, Web of Science, EMBASE, Cochrane Library, China National Knowledge Infrastructure (CNKI), and China Wanfang databases were comprehensively searched up to September 2020, to identify the relationship between ERCC1 rs11615 polymorphism and chemosensitivity of ovarian cancer. The data was analyzed by Stata 15.0 statistic software. Results A total of 10 published papers were included, including 1866 patients with ovarian cancer. The results showed that compared allele C at ERCC1 rs11615 locus with allele T, the pooled OR was 0.92 (95%CI:0.68 ~ 1.24, P > 0.05). There were no significant differences in recessive, dominant, homozygous, and heterozygous models. In accordance with a subgroup analysis of Ethnicity, all genotypes were statistically significant in the Asian population. In the allelic, dominant, recessive, homozygous and heterozygous models, the OR was 0.70 (95%CI:0.51 ~ 0.95), 0.20 (95%CI:0.07 ~ 0.56), 0.79 (95%CI:0.63 ~ 1.00), 0.21 (95%CI:0.07 ~ 0.59), 0.19 (95%CI:0.07 ~ 0.54), respectively, while in the Caucasian population, no statistically significant genotype was found. Conclusion The ERCC1 rs11615 polymorphism is associated with chemosensitivity in patients with ovarian cancer, especially in the Asian population, but not in the Caucasian population.

scholarly journals Yes-Associated Protein 1 as a Novel Prognostic Biomarker for Gastrointestinal Cancer: A Meta-Analysis

2018 ◽  
Vol 2018 ◽  
pp. 1-10 ◽  
Author(s):  
Luo Zhang ◽  
Xing Song ◽  
Xiaodong Li ◽  
Changping Wu ◽  
Jingting Jiang
Keyword(s):  
Gastrointestinal Cancer ◽  
Poor Prognosis ◽  
Web Of Science ◽  
Prognostic Biomarker ◽  
Meta Analysis ◽  
Hippo Pathway ◽  
Cochrane Library ◽  
Prognostic Effect ◽  
Hazard Ratios ◽  
The Relationship

Background. Yes-associated protein 1 (YAP1) is an effector of Hippo pathway, which plays a significant role in cell proliferation and tumor progression. The relationship between YAP1 and gastrointestinal cancer has been explored in many previous studies. We conducted a meta-analysis to explore the prognostic effect of YAP1 in patients with gastrointestinal cancer.Methods. A systematic search was performed through the PubMed, Web of Science, Embase, and Cochrane library databases to collect eligible studies. The pooled hazard ratios (HRs) with 95% confidence intervals (CIs) were used to evaluate the relationship between YAP1 expression and gastrointestinal cancer clinical outcomes.Results. A total of 2941 patients from 18 studies were enrolled. The results showed that elevated YAP1 expression predicted a poor prognosis in gastrointestinal cancer (HR = 1.56; 95% CI: 1.29-1.89;P< 0.001). Subgroup analyses indicated significant association between YAP1 overexpression and shorter OS of patients with esophageal squamous cell carcinoma (HR = 1.85; 95% CI: 1.25-2.73;P= 0.002), gastric cancer (HR = 1.41,95% CI: 1.02-1.95;P= 0.037), and colorectal cancer (pooled HR = 1.75; 95% CI: 1.42-2.15;P< 0.001). However, YAP1 expression did not affect DFS of patients with gastrointestinal cancer (pooled HR = 1.33; 95% CI: 0.95-1.88;P= 0.101).Conclusion. Elevated YAP1 expression in patients with gastrointestinal cancer might be related to shorter OS. YAP1 protein could serve as a potential predictor of poor prognosis in gastrointestinal cancer.

scholarly journals Renal cell carcinoma: a systematic review and meta-analysis on expression of androgen receptor

2018 ◽  
Vol 5 (11) ◽  
pp. 2820-2826
Author(s):  
Hossein Abdi ◽  
Hamid Reza Mozaffari ◽  
Mehrdad Payandeh ◽  
Edris Sadeghi
Keyword(s):  
Androgen Receptor ◽  
Web Of Science ◽  
Meta Analysis ◽  
Tumor Grade ◽  
Cochrane Library ◽  
Low Grade ◽  
Version 2.0 ◽  
Role Of It ◽  
The Relationship

Background: Chromosome Xq11-12 is the place that the androgen receptor (AR) sequence appears. Herein, the prevalence of this biomarker and its relation with pT stage and tumor grade was reported. Methods: Four online sites (PubMed, Scopus, Web of Science, and Cochrane Library) have been searched up to Sep 2018 systematically. Meta-Analysis software version 2.0 (CMA 2.0) and STATA 14.0 statistical software were utilized. Publication bias did not exist. Results: From the initial 1141 articles identified from the systematically searches. At last, nine of them remained for analysis. The meta-analysis included 1447 patients that 345 of them had AR expression. AR expression significantly correlated with low tumor grade and low tumor pT stage. Conclusion: AR expression was 28.2%, and it had the relationship with tumor low grade and low pT stage. Additional studies required to figure out the role of it on RCC patients.

scholarly journals Effect of ARID1A mutation and expression on prognosis of hepatocellular carcinoma and cholangiocarcinoma: a meta-analysis

2020 ◽  
Author(s):  
Guangxiao Meng ◽  
Lun-Jie Yan ◽  
Zhao-Ru Dong ◽  
Zhi-Qiang Chen ◽  
Ya-Fei Yang ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Web Of Science ◽  
Malignant Tumors ◽  
Meta Analysis ◽  
Cochrane Library ◽  
Mutation Carriers ◽  
New Treatments ◽  
The Cochrane Library ◽  
The Impact ◽  
The Relationship

Abstract Background: Hepatocellular carcinoma (HCC) and cholangiocarcinoma are the most common liver malignant tumors worldwide. Investigating the molecular basis of these malignancies is vital to the development of new treatments. Recent studies have found that mutation and abnormal expression of ARID1A, are frequently shown in HCC and cholangiocarcinoma. Herein, we aimed to estimate the effects of ARID1A mutation and expression on prognosis of HCC and cholangiocarcinoma.Methods: We searched PubMed, EMBASE, Web of Science, the Cochrane Library for studies evaluating the relationship between ARID1A mutations or expression and the survival of HCC or cholangiocarcinoma patients. Meta-analysis was performed to generate a combined HR with a 95% confidence interval (CI) for overall survival (OS).Results: We identified 12 articles that evaluated the impact of ARID1A mutation or expression on the prognosis of patients with HCC or cholangiocarcinoma. Six studies provided data on HCC survival and 6 studies examined cholangiocarcinoma survival. For HCC, ARID1A mutation carriers or patients with low ARID1A expression had worse OS (HR = 1.75; 95% CI = 1.22–2.51) than non-carriers or patients with high ARID1A expression. For cholangiocarcinoma, ARID1A mutation carriers or patients with low ARID1A expression also had significantly shorter OS (HR = 3.70, 95% CI = 2.88–4.76).Conclusions: Our study suggests that ARIDIA mutation or low expression is strongly associated with poor prognosis of patients with HCC or cholangiocarcinoma, and may be considered as a potential prognostic biomarker for these patients.

scholarly journals Association of LTF, ENAM, and AMELX polymorphisms with dental caries susceptibility: A meta-analysis

2020 ◽  
Author(s):  
Roohollah Sharifi ◽  
Sajjad Jahedi ◽  
Hamid Reza Mozaffari ◽  
Mohammad Moslem Imani ◽  
Masuod Sadeghi ◽  
...  
Keyword(s):  
Dental Caries ◽  
Web Of Science ◽  
Meta Analysis ◽  
Cochrane Library ◽  
Control Group ◽  
Case Group ◽  
Caries Risk ◽  
Increased Risk ◽  
Dental Caries Susceptibility ◽  
Review Manager

Abstract Background: This meta-analysis evaluated the association of LTF, ENAM, and AMELX polymorphisms with dental caries susceptibility. Methods: We searched the Scopus, PubMed/Medline, Web of Science, and Cochrane Library databases to retrieve articles published by October 2019. Review Manager 5.3 software was used to estimate the odds ratios (ORs) and 95% confidence intervals (CIs). The results of publication bias tests were retrieved by Comprehensive Meta-Analysis 2.0 software. Results: A total of 150 relevant records were identified; out of which, 16 were entered into the analysis (4 studies assessed LTF, 11 ENAM, and 11 AMELX polymorphisms). Of all polymorphisms, there was a significant association only between ENAM rs3796704 polymorphism and dental caries susceptibility. Both ENAM rs3796704 and AMELX rs17878486 polymorphisms had a significant association with dental caries risk in the Caucasian ethnicity and the studies including caries-free control group. Conclusions: The results of this meta-analysis showed that the G allele and the GG genotype of ENAM rs3796704 were associated with an increased risk of caries in the case group compared with the control group. But there was no association between LTF rs1126478, ENAM (rs1264848 and rs3796703), and AMELX (rs946252, rs17878486, and rs2106416) polymorphisms and dental caries susceptibility.

scholarly journals Association of LTF, ENAM, and AMELX polymorphisms with dental caries susceptibility: A meta-analysis

2020 ◽  
Author(s):  
Roohollah Sharifi ◽  
Sajjad Jahedi ◽  
Hamid Reza Mozaffari ◽  
Mohammad Moslem Imani ◽  
Masuod Sadeghi ◽  
...  
Keyword(s):  
Dental Caries ◽  
Web Of Science ◽  
Meta Analysis ◽  
Cochrane Library ◽  
Control Group ◽  
Case Group ◽  
Caries Risk ◽  
Increased Risk ◽  
Dental Caries Susceptibility ◽  
Review Manager

Abstract Background This meta-analysis evaluated the association of LTF , ENAM , and AMELX polymorphisms with dental caries susceptibility. Methods We searched the Scopus, PubMed/Medline, Web of Science, and Cochrane Library databases to retrieve articles published by October 2019. Review Manager 5.3 software was used to estimate the odds ratios (ORs) and 95% confidence intervals (CIs). The results of publication bias tests were retrieved by Comprehensive Meta-Analysis 2.0 software. Results A total of 150 relevant records were identified; out of which, 16 were entered into the analysis (4 studies assessed LTF , 11 ENAM , and 11 AMELX polymorphisms). Of all polymorphisms, there was a significant association only between ENAM rs3796704 polymorphism and dental caries susceptibility. Both ENAM rs3796704 and AMELX rs17878486 polymorphisms had a significant association with dental caries risk in the Caucasian ethnicity and the studies including caries-free control group. Conclusions The results of this meta-analysis showed that the G allele and the GG genotype of ENAM rs3796704 were associated with an increased risk of caries in the case group compared with the control group. But there was no association between LTF rs1126478, ENAM (rs1264848 and rs3796703), and AMELX (rs946252, rs17878486, and rs2106416) polymorphisms and dental caries susceptibility.

Sign in / Sign up

Export Citation Format

Share Document